Search for new alpha1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
Affiliations
- PMID: 19675810
- PMCID: PMC2721542
Item in Clipboard
Search for new alpha1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
Indian J Urol.
2007 Apr.
No abstract available
Similar articles
-
New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.Int J Urol. 2012 Apr;19(4):306-16. doi: 10.1111/j.1442-2042.2011.02957.x. Epub 2012 Jan 17. Int J Urol. 2012. PMID: 22251148 Review.
-
A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.J Urol. 2006 Sep;176(3):1236-41. doi: 10.1016/j.juro.2006.04.029. J Urol. 2006. PMID: 16890732
-
Effects of isocorynoxeine, from Uncaria, on lower urinary tract dysfunction caused by benign prostatic hyperplasia via antagonism of α1A-adrenoceptors.Toxicol Appl Pharmacol. 2019 Aug 1;376:95-106. doi: 10.1016/j.taap.2019.05.018. Epub 2019 May 27. Toxicol Appl Pharmacol. 2019. PMID: 31145917
-
Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia.Expert Opin Investig Drugs. 1999 Dec;8(12):2073-2094. doi: 10.1517/13543784.8.12.2073. Expert Opin Investig Drugs. 1999. PMID: 11139841
-
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Clin Drug Investig. 2015 Feb;35 Suppl 1:7-18. doi: 10.1007/s40261-014-0257-3. Clin Drug Investig. 2015. PMID: 25708606 Review.
Cited by
-
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia.Rev Urol. 2008 Spring;10(2):85-91. Rev Urol. 2008. PMID: 18660858 Free PMC article.
References
-
- Kawabe K, Yoshida M, Homma Y. Silodosin Clinical Study Group. Silodosin, a new alpha adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24. - PubMed
-
- AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–47. - PubMed
-
- Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51:892–900. - PubMed
-
- Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998;51:901–6. - PubMed
-
- Takei R, lkeqaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha 1 adrenoreceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha 1-adrenoreceptors. Jpn J Phrmacol. 1999;79:447–54. - PubMed
